India Pharma Department To Push Bulk-Drug Industry Focus To New PM
This article was originally published in PharmAsia News
India's Department of Pharmaceuticals is expected to recommend to the new Narendra Modi administration that it provide support for building the bulk drug part of the nation's pharmaceutical industry.
You may also be interested in...
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
With many competitor programs on hold during the COVID crisis, L’Oreal dialed up its media investments and launched products over the summer that were postponed from the first quarter, resulting in a return to growth in the firm’s third quarter led by Professional Products and Active Cosmetics.
Just as the MDR and IVDR are being implemented, increasing regulatory divergence in Europe is a growing danger to patient safety throughout the EU. Erik Raadsheer, senior director of Align Technology, expressed concerns.